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Abstract
In addition to methods that can identify common variants associated with susceptibility to common diseases, there
has been increasing interest in approaches that can identify rare genetic variants. We use the simulated data
provided to the participants of Genetic Analysis Workshop 17 (GAW17) to identify both rare and common single-
nucleotide polymorphisms and pathways associated with disease status. We apply a rare variant collapsing
approach and the usual association tests for common variants to identify candidates for further analysis using
pathway-based and tree-based ensemble approaches. We use the mean log p-value approach to identify a top set
of pathways and compare it to those used in simulation of GAW17 dataset. We conclude that the mean log p-
value approach is able to identify those pathways in the top list and also related pathways. We also use the
stochastic gradient boosting approach for the selected subset of single-nucleotide polymorphisms. When
compared the result of this tree-based method with the list of single-nucleotide polymorphisms used in dataset
simulation, in addition to correct SNPs we observe number of false positives.
Background
Many genome-wide association studies (GWAS) have
been conducted in the search for specific genetic var-
iants associated with common diseases. In testing for
association with common polymorphisms, those variants
that were identified were able to explain a modest pro-
portion of disease heritability. This led to the hypothesis
that multiple rare variants may play a role in complex
disease etiology [1][2][3]. The multiple rare variants or
common disease/rare variant hypothesis states that mul-
tiple rare variants with moderate to high penetrances
underlie the susceptibility to a common disease. It is
likely that both common and rare genetic variants con-
tribute to disease risk.
Approaches targeted at uncovering associations
between common polymorphisms and disease are gener-
ally underpowered for detecting the influence of rare
variants. To identify disease-associated rare variants,
investigators have proposed several methods based on
the collapsing of low-frequency single-nucleotide poly-
morphisms (SNPs) [4-7].
In this analysis we use the methods proposed by Li
and Leal [4] and Morris and Zeggini [8] to identify rare
variants, and we use association analysis to identify
common variants that confer liability to disease. The
rationale behind this collapsing approach is that
although the probability that an individual carries more
than one rare allele may be low, in aggregate rare alleles
may be common enough to account for variation in
common traits. The goal is then to test for an associa-
tion of an accumulation of rare minor alleles with the
disease trait, by combining information across multiple
variant sites.
We begin our analyses with the collapsing methods
and extend the analyses in two ways. First, we use the
mean log p-value (MLP) [9], which is a method that
takes into account information about SNP function and
ontologic pathway. The MLP can be thought of as a
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way to group together SNPs by their functional implica-
tion. It was originally developed for the analysis of gene
expression data for a better understanding of the under-
lying mechanisms. Thus, by further analyzing the results
of the rare variant collapsing approach using MLP ana-
lysis, we exploit both the spatial and the functional asso-
ciations of SNPs implicated in a disease. Second, we use
an empirical approach, stochastic gradient boosting
(SGB), to discern groups of SNPs conferring liability to
disease. SGB is an ensemble tree-based method [10] that
is useful for empirically detecting sets of genes asso-
ciated with a disease.
Methods
Data
Our analyses focus on the case-control data provided to
the participants of Genetic Analysis Workshop 17 [11].
We selected the first of 200 simulated replicates for ana-
lysis. We conducted the Hardy-Weinberg equilibrium
test using PLINK [12] and excluded from further analy-
sis all markers with deviations (p-value less than 0.0001
in control subjects). We conducted population stratifica-
tion analysis by first excluding correlated markers and
then using the multidimensional scaling methods in
PLINK.
Significant markers
We use the collapsing method proposed by Li and Leal
[4] and Morris and Zeggini [8] to identify possible var-
iants among rare SNPs. For this analysis we use the
CCRaVAT (Case-Control Rare Variant Analysis Tool)
software package [13]. The collapsing method is as fol-
lows: first, we divide the markers into groups on the
basis of predefined criteria (either genes or sliding win-
dows of defined sequence length); next, we collapse
marker data based on an indicator variable that shows
whether a subject carries any rare variants; and finally,
using a Pearson chi-square test, we test the significance
of the difference in proportions between case subjects
and control subjects who carry rare variant minor
alleles. When cell counts are small, we use a Fisher
exact test instead.
We consider several approaches for the collapsing cri-
terion, including gene-based collapsing and sliding win-
dows of five different sizes (1 kb, 5 kb, 25 kb, 50 kb,
and 100 kb). The resulting p-values are recorded for
further analysis. In addition, we test the common variant
SNPs using the Pearson chi-square test. Again, the
resulting p-values are retained for further analysis.
MLP approach
We use the MLP approach [9] to incorporate functional
and pathway information about genes into our analysis.
The MLP analysis was developed in the context of gene
expression analysis. The idea is to first assign a statistic
(e.g., a p-value) to each gene. The genes are mapped
onto gene sets or pathways by utilizing gene annotation
databases, such as the Kyoto Encyclopedia of Genes and
Genomes (KEGG) [14], the Ingenuity Pathway Analysis
(IPA) [15], and the Gene Ontology (GO) Biological Pro-
cesses databases [16]. Permutation tests are used to
determine a p-value for a gene set and to identify the
top set of gene sets.
In our analysis, we explore both rare and common
variants. To assign a p-value to a gene, we use the
results of collapsing and association tests. Thus a gene
can have multiple p-values associated with it, especially
in the rare variant analysis, because the windows over-
lap. We examine several ways to assign the p-value to a
gene in order to explore the utility of each, three for
rare variants and two for common variants. For rare var-
iants, we use (1) the p-value from the association test
based on gene-wise collapsing or (2) the minimum p-
value among association tests based on the collapsing
within 5-kb sliding windows located in a gene. This win-
dow size is based on the preliminary explorations of
varying window sizes ranging from 1 kb to 100 kb. In
addition, we use (3) the mean log p-value among asso-
ciation tests based on the collapsing within 5-kb sliding
windows located in a gene. For common variants, we
use either (1) the minimum p-value among SNPs in a
gene or (2) the mean log p-value among SNPs in a gene.
We create gene sets, consisting of groups of genes, on
the basis of one of the databases (KEGG, IPA, or GO).
The gene set statistic is subsequently calculated as the
MLP of the gene statistics for each gene set. The per-
mutation procedure described by Raghavan et al. [9] is
used to obtain the gene set p-value. The gene sets are
rank-ordered by p-value. We examine the top 20 sets
and present the top 6 sets in this report.
Stochastic gradient boosting
SGB [10] is an ensemble tree-based method that uses an
independently drawn random sample of individuals and
SNPs to construct a small tree, typically containing 2 to
12 terminal nodes. The tree is grown as a result of
recursively partitioning a node and contributes a small
portion to the overall model. Each consecutive tree is
built for the prediction residuals (from all preceding
trees) of an independently drawn random sample. The
final SGB model and its prediction perform by combin-
ing weighted individual tree contributions, with weight
being a shrinkage parameter appropriately selected to
reduce overfitting.
The SGB method produces a variable importance
measure that can be used to identify top predictors. For
tree methods variable importance scores show the rela-
tive contribution of each of the variables to predicting
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the outcome. For ensemble methods, such as SGB, the
variable importance scores are averaged across all trees.
We apply the SGB method, using TreeNet, developed
by Salford Systems [17], to the data consisting of the
first replicate of the affected phenotype, multidimen-
sional scaling components, environmental predictors
(Age, Smoke, and Sex), and SNPs. We start with a set of
the top common and rare SNPs passed from the collap-
sing approach and association tests. We then use the set
of all SNPs provided in the GAW17 dataset.
Results
The initial data analysis of minor allele frequencies
(MAFs) in the case-control data showed 3,224 rare var-
iants (MAF between 1% and 5%) and 18,131 very rare
variants (MAF less than 1%). There were 209 (30%)
affected case subjects and 488 (70%) unaffected control
subjects. Twenty-nine percent of males and thirty-one
percent of females were affected. Smoking differed with
case status. Smoking was prevalent in 35.9% of the
affected subjects, in contrast to 21.7% of the unaffected
subjects. After filtering, the data set included 22,615
SNPs. The population stratification results (the first two
components) are shown in Figure 1. Three clusters were
identified, corresponding to three populations. The
resulting dimensions were carried forward for
stratification.
We performed collapsing for various window sizes (1
kb, 5 kb, 25 kb, 50 kb, and 100 kb) as well as gene-wise
collapsing. The Manhattan plot of p-values produced by
the collapsing approach for 5-kb sliding windows is
shown in Figure 2. The results from the 5-kb analysis
were carried into further analyses.
We used the MLP approach to identify the top gene
sets based on the KEGG, IPA, and GO databases. We
examined the results from the MLP analysis using IPA
pathways in greater detail, because this was the database
used to simulate the GAW17 data. The top 20 gene sets
were examined. Results for the top six sets are summar-
ized in Table 1. The three gene statistics for rare var-
iants and the two gene statistics for common variants
described in the “MLP Approach” subsection of the
Methods section are presented. The top gene sets based
on the minimum of window p-values shows the Notch,
Hypoxia, Nitric Oxide, and vascular endothelial growth
factor (VEGF) signaling pathways. Both the VEGF and
the Notch signaling pathways control initiation and dif-
ferentiation in angiogenesis, a process leading to blood
vessel formation or remodeling. The VEGF pathway is
also among the top 15 pathways identified using the
KEGG database and the same statistic (results not
shown).
We applied the SGB approach to the data containing
preselected SNPs, population stratification results, and
environmental variables. We used TreeNet to perform
the SGB. We built 5,000 trees (iterations) with a maxi-
mum of 8 nodes. We chose a shrinkage parameter of
0.01 as appropriate for a data set of this dimension
[18,19]. The top set of SNPs was selected using a vari-
able importance measure of 7.00 as a cutoff threshold.
The corresponding genes were also recorded. The
results of the SGB approach are shown in Table 2. The
table contains the top SNPs selected and their corre-
sponding genes. The results that match the simulated
model are shown in bold. The SGB analyses using the
complete set of SNPs did not show an improvement
over prior runs (results not shown).
The MLP approach correctly placed the VEGF signal-
ing pathway and the two pathways related to the cardio-
vascular system (Hypoxia and Nitric Oxide) among the
top six pathways. There are only 5 (out of 216) SNPs
correctly identified using the SGB approach; their MAFs
range from 0.2% to 17%. Most of the SNPs (211) placed
in the top list are false positives.
Discussion and conclusions
Traditionally, GWAS test for association of disease with
common polymorphisms. Polymorphisms with popula-
tion frequencies of 5% or more could be tested directly
or indirectly for association with disease risk or quanti-
tative traits, and GWAS have identified many genetic
variants associated with disease traits. Replication of
these results has not been consistently successful. More
recently, methods have been proposed to identify multi-
ple rare variants with small individual effect sizes that
Figure 1 Plot of the first two components of multidimensional
scaling
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may be implicated in complex multigenic diseases.
These methods are based on grouping rare variants by
their physical proximity in order to combine informa-
tion across them. According to Hirschhorn [20], one of
the primary goals of GWAS is to discover the biologic
pathways underlying polygenic diseases.
The MLP method is an effort in this direction, where
both common and rare variants are considered on the
basis of their functional implication in disease etiology.
Our goal here was to exploit both the spatial and the
functional associations of SNPs implicated in a disease
to identify the underlying biologic pathways. Pathways
used to simulate the affection status in the GAW17 data
set were among the top four pathways identified by the
MLP approach based on statistic 2 for rare variants.
More specifically, the three pathways (Hypoxia, Nitric
Oxide, and VEGF) were used to simulate the data. In
addition, as explained in what follows, the top four
pathways, including the Notch pathway, may be part of
a cascade of interrelated pathways. Enriched signaling
pathways in our analysis may overlap functionally and
indicate processes leading to angiogenesis. Hypoxia sig-
naling can trigger the VEGF cascade in cancer tissue
angiogenesis, and the Notch processes downstream from
the Hypoxia and VEGF pathways lead to a differentia-
tion of newly formed vessels. Notch signaling can also
down-regulate VEGF expression in a feedback loop.
Thus the MLP approach based on statistic 2 for rare
variants appears to be able to also identify related path-
ways and may be promising for the discovery of biologi-
cal pathways implicated in disease etiology by rare
variants.
One of the goals of this analysis was to compare
results from a variety of functional and pathway data-
bases and from a number of gene statistics. Our results
indicate that using the IPA database, the gene statistic
that identified the most relevant pathways was the mini-
mum p-value derived from collapsing rare variants
within 5-kb sliding windows residing in a gene. These
results highlight the importance of using the most
appropriate pathway database for the analysis, an aspect
not explicitly discussed in the literature. Our analysis
Figure 2 Manhattan plot of collapsing approach p-values for 5-kb sliding window
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also indicates that (1) the results can be influenced by
the density of coverage of rare variant SNPs in a gene;
(2) gene-based collapsing may be too broad and may
dilute the underlying information; and (3) using the
mean of the window p-values may mute the signal con-
siderably. In future work, we will evaluate alternative
approaches to mapping SNP-level p-values to gene-level
p-values as well as methods for combining the rare and
common variants analyses.
The top pathways identified using the MLP method
intersect with the pathways that contain genes from the
results of the SGB approach. There are 5 correct SNPs
out of 216 residing in 5 correct genes out of 188 corre-
sponding to the top selected SNPs. The large number of
false positives may be due to correlation of the SNPs
identified by the SGB approach with the true SNPs used
in the simulation model. Our current work includes
studying methods to bridge the two approaches utilizing
the functional information and the statistical correlation,
respectively.
Currently, many analytic strategies rely on GWAS
with one-SNP-at-a-time analyses. Although this
approach has certainly yielded many promising candi-
dates, it requires large samples to mitigate type I errors.
One-SNP-at-a-time analyses generally do not take
advantage of all the information present in the data, and
failure of replication is commonplace. Recent attempts
have been made to incorporate information from rare
variants into the analysis by aggregating across SNPs
that are in close proximity to each other. We have
extended this further by leveraging information from
SNPs that are either functionally related (MLP
Table 1 Major IPA pathways identified by the MLP approach using five statistics for rare and common variants and
their corresponding p-values
Statistic Top 6 pathways selected p-value
Rare variants
Gene-wise collapsing 1. Androgen and estrogen metabolism 0.0006
2. Sphingolipid metabolism 0.0006
3. Phenylalanine metabolism 0.0015
4. Death receptor signaling 0.002
5. Stilbene, coumarine, and lignin biosynthesis 0.0036
6. TWEAK signaling 0.0043
Minimum p-value of 5-kb sliding window collapsing within a gene 1. Notch signaling 0.0248
2. Hypoxia signaling in the cardiovascular system 0.0403
3. Nitric oxide signaling in the cardiovascular system 0.0409
4. VEGF signaling 0.0585
5. Glutamate receptor signaling 0.0642
6. Glutamate metabolism 0.0741
Mean log p-value of 5-kb sliding window collapsing within a gene 1. Cyanoamino acid metabolism 0.0032
2. Ubiquinone biosynthesis 0.0148
3. Nitrogen metabolism 0.0267
4. Alanine and aspartate metabolism 0.0392
5. GABA receptor signaling 0.0423
6. FXR/RXR activation 0.0438
Common variants
Minimum p-value among SNPs 1. Apoptosis signaling 0.0083
2. Pyrimidine metabolism 0.0232
3. CNTF signaling 0.0429
4. FLT3 signaling in hematopoietic progenitor cells 0.0601
5. Role of NANOG in mammalian embryonic stem cell pluripotency 0.0847
6. EGF signaling 0.0908
Mean log p-value for SNPs in a gene 1. Pyrimidine metabolism 0.0021
2. CNTF signaling 0.0127
3. Melanocyte development and pigmentation signaling 0.0221
4. JAK/Stat signaling 0.0327
5. IL-15 signaling 0.0356
6. FLT3 signaling in hematopoietic progenitor cells 0.045
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Table 2 Top SNPs and corresponding genes identified using the SGB approach
Top SNPs identified (from highest to lowest variable importance)
SNPs C13S523 C9S3621 C6S6142 C5S237 C9S4860 C22S1374 C2S5630 C11S60
C13S905 C1S6542 C7S2893 C19S282 C6S1097 C10S2632 C2S955 C14S784
C1S5779 C7S2446 C9S1469 C12S4668 C2S1087 C2S2148 C1S10506 C6S2129
C15S3343 C12S4188 C14S1863 C2S4601 C6S2469 C10S2533 C19S609 C10S5515
C1S5530 C17S3017 C9S1225 C13S522 C12S3028 C5S3461 C19S1762 C1S9584
C19S1849 C9S4013 C22S1405 C12S622 C12S7056 C2S7558 C16S3421 C12S552
C2S4407 C1S996 C22S1351 C20S2310 C22S1158 C15S4060 C17S1262 C3S1305
C7S158 C10S387 C17S2377 C7S1877 C1S9718 C10S4422 C4S2872 C7S3971
C2S689 C8S3322 C10S6566 C14S20 C7S1076 C11S3224 C1S7413 C22S146
C8S4238 C8S4028 C18S2322 C6S6040 C12S5220 C6S6177 C19S3382 C19S2528
C1S9506 C4S4283 C12S3528 C11S2585 C17S2376 C12S5446 C17S4841 C1S10200
C4S2239 C7S3613 C5S4072 C11S6503 C11S4881 C1S10800 C9S123 C2S7414
C2S1139 C3S3962 C7S3490 C10S5783 C11S1683 C9S2613 C11S2532 C7S4111
C18S2310 C2S4079 C6S2366 C8S627 C2S6985 C1S7941 C11S5292 C4S4339
C3S3938 C6S5380 C22S875 C1S7092 C7S2590 C11S2871 C6S2216 C6S5677
C7S4646 C8S850 C8S271 C4S2296 C10S386 C9S5111 C15S3138 C1S7427
C17S3510 C3S96 C22S385 C1S3900 C3S4638 C21S672 C1S1388 C10S2683
C13S1168 C7S3697 C2S4909 C11S1280 C2S2154 C12S4591 C3S1176 C22S2039
C11S3320 C2S873 C9S3100 C2S7390 C12S5526 C11S1599 C6S4552 C1S10256
C10S3243 C12S5510 C4S2678 C4S2970 C2S8207 C16S560 C6S7138 C17S321
C20S1844 C12S5445 C10S2670 C1S4009 C17S2026 C9S3554 C13S1660 C14S590
C10S6432 C9S759 C19S4625 C1S9511 C8S934 C6S4242 C18S1560 C4S97
C15S3744 C7S397 C19S4658 C12S4534 C9S2083 C19S5271 C7S3898 C1S4838
C9S1607 C4S3834 C11S5644 C15S2848 C10S3777 C3S3657 C14S122 C14S3426
C16S1482 C4S3076 C9S2542 C2S6995 C21S778 C9S1835 C15S3559 C8S3416
C5S2032 C1S10813 C10S5690 C1S3676 C6S4400 C13S163 C22S645 C12S3039
C1S10164 C6S7164 C22S1222 C4S649 C19S277 C1S7408 C1S1542 C4S186
Genes TNFRSF25 AHSA2 ADH1B GPR85 OR13C5 SYTL2 PSME2 PTPRS
ARHGEF10L RGPD3 C4ORF33 PTPRZ1 CDK5RAP2 PDGFD VTI1B OR10H3
KIF17 RGPD4 TKTL2 PAX4 STOM EXPH5 BEGAIN CYP4F2
PDE4B ACVR1C ANP32C SMO GOLGA1 OR8D4 PAQR5 ZNF486
PTGER3 LY75 PLEKHG4B ZC3HC1 BRD3 CLEC2D TSPAN3 NPHS1
MSH4 PPIG ZNF474 AKR1B1 CARD9 KLRK1 ADAMTS7 ZNF576
STXBP3 WDR75 ABLIM3 SLC37A3 ECHDC3 OR6C1 ALPK3 LYPD5TMC4
HIPK1 LOC729332 FOXI1 GATA4 ERCC6 OR6C65 SLC28A1 C20ORF32
VTCN1 UGT1A10 PGBD1 TNFRSF10D PGBD3 SRGAP1 AKAP13 PRIC285
ARNT COL6A3 BAT2 CDCA2 HKDC1 PLXNC1 ZNF213 PIGP
ADAM15 MTERFD2 SLC44A4 PTK2B MAT1A C12ORF63 USP31 ETS2
OR10J1 CRELD1 PSMB8 EXT1 CYP2C8 CHPT1 LOC100132786 HIRA
OR10J5 LOC100130135 MDN1 SAMD12 SORCS1 TRAFD1 TRPV3 ARVCF
UAP1 SETD2 VNN1 MLZE CASP7 CAMKK2 KCNJ12 TOP3B
LRRN2 GOLGB1 FUCA2 TG DCLRE1A ANAPC5 SLFN13 SUSD2
NUAK2 TMCC1 UTRN ANKRD15 TACC2 ZNF26 PIP4K2B SEC14L3
IKBKE TRPC1 AGPAT4 PDCD1LG2 ATHL1 TNFRSF19 BRCA1 SMTN
LAMB3 CRIPAK PMS2 AQP3 GALNTL4 FLT1 FAM117A LIMK2
DUSP10 GRK4 TSPAN13 C9ORF131 HPS5 TRPC4 RECQL5 LOC100132621
KIAA0133 AFAP1 NPC1L1 NPR2 NELL1 FREM2 HRH4
ARL6IP2 PF4V1 NCF1 POLR1E OR8H1 PIBF1 B4GALT6
OXER1 STBD1 FBXO24 SMC5 OR9G4 RNASE6 MCART2
FSHR FAM13A1 FBXL13 C9ORF79 OR4D9 FLJ10357 ZNF57
BCL11A PDLIM5 RELN ROR2 AHNAK ACIN1 ZNF77
Boldface indicates results that match the simulated model.
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approach) or statistically correlated (SGB approach) with
the hope of obtaining results that are credible and logi-
cally interpretable. These methods would, of course,
need to be further evaluated in other data sets and
other settings.
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